1. Home
  2. CPAY vs INCY Comparison

CPAY vs INCY Comparison

Compare CPAY & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Corpay Inc.

CPAY

Corpay Inc.

N/A

Current Price

$453.50

Market Cap

25.8B

Sector

Technology

ML Signal

N/A

Logo Incyte Corp.

INCY

Incyte Corp.

N/A

Current Price

$118.76

Market Cap

24.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CPAY
INCY
Founded
1986
1991
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Commercial Physical & Biological Resarch
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.8B
24.5B
IPO Year
2010
1994

Fundamental Metrics

Financial Performance
Metric
CPAY
INCY
Price
$453.50
$118.76
Analyst Decision
Buy
Buy
Analyst Count
16
28
Target Price
★ $496.67
$132.25
AVG Volume (30 Days)
441.3K
★ 1.6M
Earning Date
11-04-2026
10-29-2026
Dividend Yield
N/A
N/A
EPS Growth
7.59
★ 4173.33
EPS
★ 14.44
0.50
Revenue
★ $4,528,403,000.00
$3,394,635,000.00
Revenue This Year
$18.27
$17.74
Revenue Next Year
$8.33
$4.35
P/E Ratio
★ $31.32
$238.20
Revenue Growth
★ 13.93
13.67
52 Week Low
$276.82
$89.25
52 Week High
$479.53
$132.60

Technical Indicators

Market Signals
Indicator
CPAY
INCY
Relative Strength Index (RSI) 63.04 50.25
Support Level $390.93 $115.38
Resistance Level $479.53 $119.29
Average True Range (ATR) 12.15 3.69
MACD 1.96 0.06
Stochastic Oscillator 66.50 45.42

Price Performance

Historical Comparison
CPAY
INCY

About CPAY Corpay Inc.

Corpay Inc is a corporate payments company that helps businesses and consumers manage and pay their expenses. The company offers payment and spend management solutions, including accounts payable automation, cross-border payments, commercial card programs, vehicle payment solutions, and lodging payment services. Its reportable segments are: Corporate Payments, Vehicle Payments, Lodging Payments and Other. The majority of the company's revenue is derived from the Vehicle Payments segment, which helps customers to pay for vehicle related expenses. Geographically, it derives the maximum revenue from the United States and the rest from Brazil, the United Kingdom and other countries.

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.

Share on Social Networks: